Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain
the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in
Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles
and JavaScript.
Cervical cancer is a disease in which the cells of the cervix become abnormal and start to grow uncontrollably. Approximately 90% are squamous cell carcinomas, and the remaining 10% are adenocarcinomas. This cancer originates in the mucus-producing cells of the inner or endocervix, near the body of the uterus.
Evidence supports the use of primary HPV testing to accelerate the global elimination of cervical cancer, but such recommendations must be viewed in the context of the fragile healthcare systems and complex implementation challenges in low-income and lower-middle income countries.
A quadrivalent vaccine against human papillomavirus produced by the Serum Institute of India was shown to be noninferior to the established quadrivalent vaccine — boosting global efforts to eliminate cervical cancer.
A WHO expert panel concluded that a single dose of HPV vaccine has efficacy comparable to that of the two-dose regimen, which could help boost cervical cancer–elimination efforts.
